Quanterix
Builds Simoa and spatial biology tools for ultra-sensitive biomarker research and diagnostics.
Something off on this page? Send us feedback.
Profile
Sells instruments, assay kits, consumables, lab services, and diagnostics-facing tests built around Simoa protein detection and Akoya spatial biology. Revenue is reported in one segment, while operations are centered in Massachusetts with most employees in the United States and a smaller international base.
Built around Simoa, the platform detects low-abundance protein biomarkers in blood, serum, and other fluids through instruments, assay kits, consumables, custom assay work, and the Simoa Accelerator Laboratory.
After the Akoya acquisition, the scope includes spatial biology instruments, reagents, software, and services for tissue analysis and spatial phenotyping. The portfolio now spans blood and tissue, with diagnostic-facing activity through Lucent Diagnostics and Alzheimer's blood-test development.
Headquartered in Billerica, Massachusetts, the employee base is concentrated in the United States with a smaller presence across foreign countries. The business depends on instrument, consumables, services, and assay adoption by research, biopharmaceutical, diagnostics, and clinical customers, plus Akoya integration and diagnostic regulatory and reimbursement execution.
Company facts
Categories
Key statistics
Year to date −58.9% · Average volume (30d) 722.3K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Aug 17, 2026 | Canaccord Genuity | Reiterate | Hold | $4 | $3 | |
| Apr 20, 2026 | Canaccord Genuity | Reiterate | Hold | $8 | $4 | |
| Dec 22, 2025 | Canaccord Genuity | Reiterate | Hold | $25 | $8 | |
| Aug 11, 2025 | Canaccord Genuity | Downgrade | Buy | Hold | ||
| Apr 30, 2025 | Leerink Partners | Downgrade | Outperform | Market Perform |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 10, 2026Q2 FY26 | −$0.41 | −$1.04 | −153.5% | $37.5M | $32.9M | −12.2% | −39.95% |
| May 6, 2026Q1 FY26 | −$0.31 | −$0.39 | −25.8% | $36.8M | $36.4M | −1.2% | −16.41% |
| Mar 2, 2026Q4 FY25 | −$0.27 | −$0.38 | −40.7% | $38.2M | $43.9M | +14.8% | −7.27% |
| Nov 10, 2025Q3 FY25 | −$0.23 | −$0.36 | −56.5% | $38.0M | $40.2M | +5.8% | −2.34% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $30.3M | $24.5M | $40.2M | $43.9M | $36.4M | $32.9M | |
| Gross profit | $16.4M | $11.3M | $17.1M | $20.0M | $15.6M | $12.7M | |
| Operating income | −$26.4M | −$37.1M | −$37.3M | −$23.9M | −$21.5M | −$49.4M | |
| Net income | −$20.5M | −$30.0M | −$33.5M | −$23.1M | −$17.5M | −$48.9M | |
| Diluted EPS | −$0.53 | −$0.77 | −$0.73 | −$0.49 | −$0.37 | −$1.04 | |
| Gross margin | 54.0% | 46.1% | 42.6% | 45.5% | 42.7% | 38.5% | |
| Operating margin | -87.1% | -151.7% | -93.0% | -54.4% | -59.1% | -150.2% |
Fiscal years (4-quarter sums)FY21 $109.5M · FY22 $105.0M · FY23 $121.4M · FY24 $135.4M · FY25 $138.7M
Revenue by product · Q2 FY26
Revenue by geography · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $93.5M · Total debt $33.4M · Total assets $319.6M · Shareholders' equity $237.2M
Dividends
No dividends on record.
Ownership
Shares outstanding 47.11M · Float 38.46M · 81.6% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 3.64M | 7.72% | 13F | Aug 7, 2026 |
| Blue Water Life Science Advisors, LP | 3.47M | 7.38% | 13F | Aug 14, 2026 |
| First Eagle Investment Management, LLC | 2.75M | 5.84% | 13F | Aug 24, 2026 |
| Telegraph Hill Partners III, L.P. | 2.50M | 5.40% | 13G | Nov 19, 2025 |
| Portolan Capital Management, LLC | 1.90M | 4.03% | 13F | Aug 14, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 13, 2026 | William P. Donnelly | director | +72,245 | $2.93 |
| Aug 12, 2026 | William P. Donnelly | director | +27,155 | $2.75 |
| May 12, 2026 | Benjamin Meadows | officer: Chief Commercial Officer | +3,500 | $2.77 |
| Sep 12, 2025 | Vandana Sriram | officer: Chief Financial Officer | +4,150 | $4.79 |
Peers
- Bio-Techne
Automated immunoassay and spatial biology workflows
- Bruker
Spatial biology platforms and multiomic services
- 10x Genomics
Single-cell and spatial genomics for tissue analysis
- Bio-Rad Laboratories
Multiplex immunoassays and clinical diagnostics scale
- Quest Diagnostics
Alzheimer's blood testing and national lab access
- Standard BioTools
Spatial proteomics tools and lab services
- Seer
Deep plasma proteomics for discovery studies
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Quanterix | $2.58 | −2.34% | $124.4M | — | — | 0.8 | +34.6% |
| Bio-Techne | $72.36 | +0.01% | $11.33B | 62.4 | 34.9 | 9.3 | +1.3% |
| Bruker | $57.08 | +0.04% | $8.69B | — | 25.2 | 2.5 | +5.2% |
| 10x Genomics | $61.54 | −0.01% | $7.81B | — | — | 12.7 | −12.7% |
| Bio-Rad Laboratories | $387.70 | +0.02% | $10.44B | 47.0 | 37.6 | 4.0 | −0.1% |
| Quest Diagnostics | $244.50 | +0.69% | $26.79B | 25.8 | 21.2 | 2.3 | +10.2% |
| Standard BioTools | $0.6548 | +2.47% | $251.3M | — | — | 3.0 | −7.6% |
| Seer | $1.97 | −1.01% | $108.9M | — | — | 7.9 | −23.4% |
| Median | 47.0 | 30.1 | 4.0 | −0.1% |